Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chandra Bhagat Pharma's EBIT per Share for the
six
months ended in Mar. 2026 was ₹6.24.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹8.11.
During the past 3 years, the average EBIT per Share Growth Rate was -11.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Chandra Bhagat Pharma's EBIT per Share or its related term are showing as below:
BOM:542934'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -11.3 Med: -6 Max: 4
Current: -11.3
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Chandra Bhagat Pharma was 4.00% per year. The lowest was -11.30% per year. And the median was -6.00% per year.
BOM:542934's 3-Year EBIT Growth Rate is ranked worse than 81.9% of 105
companies
in the Medical Distribution industry
Industry Median: 4
vs BOM:542934: -11.30
Chandra Bhagat Pharma (BOM:542934) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Chandra Bhagat Pharma EBIT per Share Related Terms
Chandra Bhagat Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Chandra Bhagat Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹8.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chandra Bhagat Pharma (BOM:542934) has a EBIT per Share of ₹8.11 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Chandra Bhagat Pharma and its competitors. According to the industry distribution chart, Chandra Bhagat Pharma ranks #86 out of 105 companies in the Medical Distribution industry, placing it in the top 81.9%.
Is Chandra Bhagat Pharma's EBIT per Share too high?
Chandra Bhagat Pharma's current EBIT per Share is ₹8.11. Based on the distribution chart, Chandra Bhagat Pharma ranks #86 out of 105 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Chandra Bhagat Pharma has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's EBIT per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Chandra Bhagat Pharma ranks #86 out of 105 companies for EBIT per Share. This places Chandra Bhagat Pharma in the lower half of its industry. The industry median EBIT per Share is 4.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 4.00, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Chandra Bhagat Pharma and its competitors. For the Medical Distribution industry, the median EBIT per Share is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandra Bhagat Pharma's current EBIT per Share is ₹8.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹70.14, compared to a current price of ₹52.50 — trading 25.1% below its estimated fair value. The current EBIT per Share is ₹8.11. Chandra Bhagat Pharma's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current EBIT per Share is ₹8.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?
Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued.
The current stock price of ₹52.50 is trading 25.1% below its estimated GF Value™ of ₹70.14.
GuruFocus considers Chandra Bhagat Pharma to be Modestly Undervalued.
Key valuation signals for BOM:542934:
EBIT per Share: ₹8.11
GF Value™: ₹70.14 vs. price of ₹52.50 (25.1% below fair value)
No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
65GF Score
Get the complete analysis for BOM:542934
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542934 has been successfully added to your 
